Matthew Klein Sells 7,371 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew Klein sold 7,371 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the transaction, the chief executive officer owned 387,082 shares in the company, valued at approximately $26,848,007.52. The trade was a 1.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

PTC Therapeutics Stock Up 1.1%

Shares of PTCT opened at $70.66 on Friday. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The stock has a fifty day simple moving average of $74.91 and a two-hundred day simple moving average of $68.02. The company has a market capitalization of $5.67 billion, a PE ratio of 9.13 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 373.67%. The firm had revenue of $164.68 million during the quarter, compared to analysts’ expectations of $281.45 million. During the same period in the prior year, the company posted ($0.85) EPS. The company’s revenue for the quarter was down 22.7% compared to the same quarter last year. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jefferies Financial Group Inc. purchased a new stake in PTC Therapeutics during the third quarter worth about $97,252,000. Janus Henderson Group PLC boosted its stake in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after purchasing an additional 1,077,776 shares during the period. State Street Corp grew its holdings in shares of PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after purchasing an additional 1,071,343 shares in the last quarter. Toronto Dominion Bank increased its stake in PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in PTC Therapeutics by 4,013.1% during the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock worth $62,945,000 after buying an additional 808,515 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on PTCT shares. Wells Fargo & Company decreased their price objective on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a report on Friday. Jefferies Financial Group upped their price target on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Cantor Fitzgerald restated an “overweight” rating on shares of PTC Therapeutics in a report on Friday. Finally, Citigroup increased their target price on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $80.73.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.